Neuralink Blindsight visual prosthesis first-in-human implant targeted for 2026 — cortical vision restoration racing Science Corp
Summary
Neuralink's Blindsight visual prosthesis — a high-density electrode array placed on the visual cortex to deliver phosphene patterns representing a camera feed for blind patients — is targeting first-in-human implant in 2026, according to the State of BCI 2026 milestones report. Neuralink CEO Elon Musk described Blindsight as their second product alongside the N1 motor BCI, targeting individuals who have lost vision due to optic nerve or retinal damage where peripheral visual pathway restoration is not possible.
Why it matters
Neuralink Blindsight racing Science Corporation PRIMA for the title of first commercial BCI product creates a fascinating two-horse competition: PRIMA targets dry AMD (retinal chip, CE mark targeting mid-2026 in Germany) while Blindsight targets optic nerve/retinal failure patients (cortical implant, first-in-human 2026). Both are racing to prove BCI can reach commercial scale beyond communication and motor restoration.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial